Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.

作者信息

Mian Agrima, Wei Wei, Hamilton Betty K, Winter Allison M, Khouri Jack, Pohlman Brad, Gerds Aaron T, Jagadeesh Deepa, Anwer Faiz, Kalaycio Matt, Dean Robert M, Sobecks Ronald, Caimi Paolo F, Hill Brian T, Majhail Navneet S

机构信息

Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Bone Marrow Transplant. 2023 May;58(5):590-593. doi: 10.1038/s41409-023-01934-4. Epub 2023 Feb 11.

DOI:10.1038/s41409-023-01934-4

PMID:36774431

Abstract

摘要

相似文献

[1]

Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.

Bone Marrow Transplant. 2023-5

[2]

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.

Blood. 2018-6-18

[3]

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

JAMA Netw Open. 2022-12-1

[4]

Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.

Leuk Lymphoma. 2022-9

[5]

Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.

Leuk Lymphoma. 2018-8

[6]

Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.

JAMA Oncol. 2020-2-1

[7]

Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.

Biol Blood Marrow Transplant. 2019-7-4

[8]

How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?

Bull Cancer. 2021-12

[9]

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol. 2018-12-2

[10]

[New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].

Bull Cancer. 2022-11

引用本文的文献

[1]

Converting TCR-based chimeric antigen receptor STAR into dual-specific targeting receptor for cancer immunotherapy.

Mol Ther. 2025-4-2

[2]

Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.

Transplant Cell Ther. 2024-6

本文引用的文献

[1]

ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy.

Am J Respir Crit Care Med. 2020-10-15

[2]

Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.

JAMA Netw Open. 2020-4-1

[3]

Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared.

Am J Respir Crit Care Med. 2019-7-1

[4]

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2018-12-1

[5]

National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment.

N Engl J Med. 2018-10-11

[6]

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med. 2017-12-28

[7]

The Promise and Challenges of CAR-T Gene Therapy.

JAMA. 2017-12-12

[8]

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Blood. 2005-10-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献